Granted Patent
B2
US 12,274,701 · App. 18/183,110 · Granted Apr 15, 2025
Compositions and methods for treating retinal degradation
A61K31/506A61K31/513A61K31/52A61K31/7052A61K31/706A61K31/7064A61K31/7068A61K31/7072A61K31/7076C07D405/04C07D411/04A61P25/16A61P25/28
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
Claims (17)
1. A method of blocking inflammasome activation, the method comprising administering to a patient in need thereof a nucleoside reverse transcriptase inhibitor (NRTI), whereby the NRTI blocks inflammasome activation, wherein the NRTI is selected from stavudine (d4T), lamivudine (3TC), abacavir (ABC), 5′-methoxy-d4T, or combinations thereof.
2. The method of claim 1 , wherein the inflammasome is selected from an NLRP3 inflammasome, a 1 L-1 beta inflammasome, and a combination thereof.
3. The method of claim 1 , wherein the inflammasome is an NLRP3 inflammasome.
4. The method of claim 1 , wherein the NRTI blocks P2X7 pore formation.
5. The method of claim 1 , wherein the NRTI blocks LPS/ATP-induced inflammasome activation.
6. The method of claim 1 , wherein the NRTI blocks Caspase-1 activation.
7. The method of claim 6 , wherein the Alu RNA level is not reduced.
8. The method of claim 1 , wherein the NRTI blocks IL-1 beta activation.
9. The method of claim 1 , wherein blocking inflammasome activation treats retinal damage in a patient having retinal damage.
10. The method of claim 9 , wherein the retinal damage is present in a retinal pigmented epithelium (RPE) cell.
11. The method of claim 1 , wherein blocking inflammasome activation treats dry age-related macular degeneration in a patient having dry age-related macular degeneration.
12. The method of claim 1 , wherein the NRTI is stavudine (d4T).
13. The method of claim 1 , wherein the NRTI is lamivudine (3TC).
14. The method of claim 1 , wherein the NRTI is abacavir (ABC).
15. The method of claim 1 , wherein the NRTI is 5′-methoxy-d4T.
16. The method of claim 1 , wherein the NRTI is a combination of at least two NRTIs selected from stavudine (d4T), lamivudine (3TC), abacavir (ABC), and 5′-methoxy-d4T.
17. The method of claim 1 , wherein the NRTI inhibits inflammasome activation by Alu RNA.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Mar 14, 2023
From: AMBATI, JAYAKRISHNA; FOWLER, BENJAMIN
To: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
Reel/Frame 062974/0562 →
Continuity (7)
Provisional Application
61987612
· May 2, 2014
Provisional Application
61861290
· Aug 1, 2013
References Cited (321)
US 5496935A
· Matthes et al.
· 1996
[cited by applicant]
US 6914054B2
· Sommadossi et al.
· 2005
[cited by applicant]
US 8809517B2
· Ambati
· 2014
[cited by applicant]
US 9326983B2
· Ambati et al.
· 2016
[cited by applicant]
US 9453226B2
· Ambati et al.
· 2016
[cited by applicant]
US 9464289B2
· Ambati
· 2016
[cited by applicant]
US 9707235B1
· Ambati
· 2017
[cited by applicant]
US 20100226931A1
· Valiante et al.
· 2010
[cited by applicant]
EP 0311100A2
· 1989
[cited by applicant]
JP 63250396
· 1987
[cited by applicant]
WO WO2011153234A2
· 2011
[cited by applicant]
WO WO2013012806A2
· 2013
[cited by applicant]
WO WO2014160336A1
· 2014
[cited by applicant]
Steinfeld, S. D., et al. “Zidovudine in primary Sjogren's syndrome.” Rheumatology 38.9 (1999): 814-817.
[cited by examiner]
Kaur et al. Journal of Clinical Rheumatology (2007), vol. 13, pp. 79-80.
[cited by examiner]
Ohrui, Hiroshi. “Development of modified nucleosides that have supremely high anti-HIV activity and low toxicity and prevent the emergence of resistant HIV mutants.” Proceedings of the Japan Academy, Series B 87.3 (2011…
[cited by examiner]
Sugar, Alan M., and Ronald P. McCaffrey. “Antifungal activity of 3′-deoxyadenosine (cordycepin).” Antimicrobial agents and chemotherapy 42.6 (1998): 1424-1427.
[cited by examiner]
Fowler, Benjamin J., et al. “Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity.” Science 346.6212 (2014): 1000-1003.
[cited by examiner]
Abdul-Sater et al., “Inflammasome-Dependent Caspase-1 Activation in Cervical Epithelial Cells Stimulates Growth of the Intracellular Pathogen Chlamydia Trachomatis,” The Journal of Biological Chemistry, 284(39): 26789-2…
[cited by applicant]
Abulafia et al., “Inhibition of the inflammasome complex reduces the inflammatory response after thromboembolic stroke in mice,” Journal of Cerebral Blood Flow & Metabolism, 29: 534-544 (2009).
[cited by applicant]
Adamczak et al., “Inflammasome Proteins in Cerebrospinal Fluid of Brain Injured Patients are Biomarkers of Functional Outcome,” J Neurosurg., 117(6): 1119-1125 (2012).
[cited by applicant]
Adinolfi et al., “Basal Activation of the P2X7 ATP Receptor Elevates Mitochondrial Calcium and Potential, Increases Cellular ATP Levels, and Promotes Serum-Independent Growth,” Mol Biol Cell, 16: 3260-3272 (2005).
[cited by applicant]
Adinolfi et al., “P2X7 Receptor Expression in Evolutive and Indolent Forms of Chronic B Lymphocytic Leukemia,” Blood, 99(2): 706-708 (2002).
[cited by applicant]
Agarwal et al., “Emtricitabine Prodrugs with Improved Anti-HIV Activity and Cellular Uptake,” Molecular Pharmaceutics, 10(2): 467-476 (2013).
[cited by applicant]
Agarwal et al., “Synthesis and Biological Evaluation of Fatty Acyl Ester Derivatives of 2′,3′-didehydro-2′3′-dideoxythymidine,” Bioorg Med Chem Lett, 21: 1917-1921 (2011).
[cited by applicant]
Ahmad et al., “Elevated Levels of circulating Interleukin-18 in Human Immunodeficiency Virus-Infected Individuals: Role of Peripheral Blood Mononuclear Cells and Implications for AIDS Pathogensis,” J Virol, 76: 12448-12…
[cited by applicant]
Aksentijevich et al., “The Clinical Continuum of Cryopyrinopathies: Novel CIAS1 Mutations in North American Patients and a New Cryopyrin Model,” Arthritis Rheum, 56(4): 1273-1285 (2007).
[cited by applicant]
Al-Khalidi et al., “Zidovudine ameliorates pathology in the mouse model of Duchenne muscular dystrophy via P2RX7 purinoceptor antagonism,” Acta Neuropathologica Communications, 6:27 (2018).
[cited by applicant]
Alcocer-Gomez et al., “NLRP3 Inflammasome: A New Target in Major Depressive Disorder,” CNS Neuroscience & Therapeutics, 20: 294-295 (2014).
[cited by applicant]
Amaral et al., “NLRP3 Inflammasome-Mediated Neutrophil Recruitment and Hypernociception Depend on Leukotriene B4 in a Murine Model of Gout,” Arthritis & Rheumatism, 64(2): 474-484 (2012).
[cited by applicant]
Ambati et al., “Age-related Macular Degeneration: Etiology, Pathogenesis, and Therapeutic Strategies,” Surv Ophthalmol, 48: 257-293 (2003).
[cited by applicant]
Ambati et al., “Mechanisms of Age-Related Macular Degeneration,” Neuron, 75: 26-39 (2012).
[cited by applicant]
Andersen et al., “Replication Across Regioisomeric Ethylated Thymidine Lesions by Purified DNA Polymerases,” Chemical Research in Toxicology, 26(11): 1730-1738 (2013).
[cited by applicant]
Andersen et al., “The NLRP3/ASC inflammasome promotes T-cell-dependent immune complex glomerulonephritis by canonical and noncanonical mechanisms,” Kidney International, 86: 965-978 (2014).
[cited by applicant]
Anderson et al., “Plasma-borne indicators of inflammasome activity in Parkinson's disease patients,” Parkinson's Disease, 7(Article No. 2): 1-12 (2021).
[cited by applicant]
Armstrong et al., “Diagnosis and treatment of Parkinson disease: a review,” JAMA, 323(6):548-580 (2020).
[cited by applicant]
Artlett et al., “The Inflammasome Activating Caspase-1 Mediates Fibrosis and Myofibroblast Differentiation in Systemic Sclerosis,” Arthritis and Rheumatism, 63(11): 3563-3574 (2011).
[cited by applicant]
Ascherio et al., “The initiation and prevention of multiple sclerosis”, Nat Rev Neural 8: 602-612 (2012).
[cited by applicant]
Ather et al., “Serum Amyloid A (SAA) Activates the NLRP3 Inflammasome and Promotes TH17 Allergic Asthma in Mice,” J Immunol, 187(1): 64-73 (2011).
[cited by applicant]
Babelova et al., “Biglycan, a Danger Signal that Activates the NLRP3 Inflammasome via Toll-like and P2X Receptors*,” The Journal of Biological Chemistry, 284(36): 24035-24048 (2009).
[cited by applicant]
Babolin et al., “TpF1 from Treponema Pallidum Activates Inflammasome and Promotes the Development of Regulatory T Cells,” The Journal of Immunology, 187: 1377-1384 (2011).
[cited by applicant]
Bakker et al., “A Tissue-Specific Role for Nlrp3 in Tubular Epithelial Repair after Renal Ischemia/Reperfusion,” The American Journal of Pathology, 184(7): 2013-2022 (2014).
[cited by applicant]
Baldini et al., “The P2X7 receptor-inflammasome complex has a role in modulating the inflammatory response in primary Sjögren's syndrome,” Journal of Internal Medicine, 274: 480-489 (2013).
[cited by applicant]
Balzarini et al., “Differential Patterns of Intracellular Metabolism of 2′,3′-didehydro-2′3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythymidine, Two Potent Anti-Human Immunodeficiency Virus Compounds,” J Biol Chem, 26…
[cited by applicant]
Bank, “Characteristics of compounds that cross the blood-brain barrier,” BMC Neurology, 9(Suppl 1):S3 (2009).
[cited by applicant]
Basso et al., “Behavioral Profile of P2X7 Receptor Knockout Mice in Animal Models of Depression and Anxiety: Relevance for Neuropsychiatric Disorders,” Behavioral Brain Research, 198: 83-90 (2009).
[cited by applicant]
Batzer et al., “Alu Repeats and Human Genomic Diversity,” Nature Review Genetics, 3:370-379 (2002).
[cited by applicant]
Bauer et al., “Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome,” Gut, 59:1192e-1199 (2010).
[cited by applicant]
Bennucci et al., “Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B,” Journal of Clinical Rheumatology, 14(4):245-246 (2008).
[cited by applicant]
Bernier., “Purinergic regulation of inflammasome activation after central nervous system injury,” J Gen Physiol, 140(5): 571-575 (2012).
[cited by applicant]
Besnard et al., “NLRP3 Inflammasome is required in murine asthma in the absence of aluminium adjuvant,” Allergy, 66(8): 1047-1057 (2011).
[cited by applicant]
Bonar et al., “Constitutively Activated NLRP3 Inflammasome Causes; Inflammation and Abnormal Skeletal Development in Mice,” Plos One, 7(4): e35979 (2012).
[cited by applicant]
Boucher et al., “Resilience and reduced c-Fos expression in P2X7 receptor knockout mice exposed to repeated forced swim test,” Neuroscience, 189:170-177 (2011).
[cited by applicant]
Bringmann et al., “Upregulation of P2X7 Receptor currents in Muller glial cells during proliferative vitreoretinopathy,” Investigative Ophthalmology & Visual Science, 42(3):860-867 (2001).
[cited by applicant]
Brydges et al., “Divergence of IL-1, IL-18, and cell death in NLRP3; inflammasomopathies,” J Clin Invest, 123(11): 4695-4705 (2013) .
[cited by applicant]
Cabrini et al., “A His-155 to Tyr polymorphism confers gain-of-function to the human P2X7 receptor of human leukemic lymphocytes,” The Journal of Immunology, 175:82-89 (2005).
[cited by applicant]
Cario-Toumaniatz et al., “P2X7 Receptor Activation-induced contraction and lysis in human saphenous vein smooth muscle,” Circulation Res, 83:196-203 (1998).
[cited by applicant]
Case et al., “Caspase-11 stimulates rapid flagellin-independent pyroptosis in response to Legionella pneumophila,” PNAS, 110(5): 1851-1856 (2013).
[cited by applicant]
Chakraborty et al., “Inflammasome Signaling At The Heart Of Central Nervous System Pathology,” Journal of Neuroscience Research, 88:1615-1631 (2010).
[cited by applicant]
Chang et al., “Inhibition of the P2Z7 receptor reduces cystogenesis in PKD,” J Am Soc Nephrol,22:1696-1706 (2011).
[cited by applicant]
Cheewatrakoolpong et al., “Identification and Characterization of Splice Variants of the Human P2X7 ATP Channel,” Biochem Biophys Res Commun, 332: 17-27 (2005).
[cited by applicant]
Chen et al., “Testing the role of P2X7 receptors in the development of type 1 diabetes in nonobese diabetic mice,” The Journal of Immunology, 186:4278-4284 (2011).
[cited by applicant]
Cheng et al., “Comparative efficacy of antiviral drugs on human ocular fibroblasts,” Exp Eye Res, 61(4): 461-467 (1995).
[cited by applicant]
Chi et al., “Caspase-8 promotes NLRP1/NLRP3 inflammasome; activation and IL-1β production in acute glaucoma,” PNAS, 111(30): 11181-11186 (2014).
[cited by applicant]
Chow et al., “NLRP3 promotes inflammation-induced skin cancer but is dispensable for asbestos-induced mesothelioma,” Immunology and Cell Biology, 90: 983-986 (2012).
[cited by applicant]
Churg et al., “The role of interleukin-1b in murine cigarette smoke-induced emphysema and small airway remodeling,” Am J Respir Cell Mol Biol, 40:482-490 (2009).
[cited by applicant]
Codolo et al., “Triggering of inflammasome by aggregated α-synuclein an inflammatory response in synucleinopathies,” Plos One, 8(1):e55375 (2013).
[cited by applicant]
Cohen et al., “A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background meth…
[cited by applicant]
Cruz et al., “ATP Activates a Reactive Oxygen Species-Dependent Oxidative Stress Response and Secretion of Proinflammatory Cytokines in Macrophages,” J Biol Chem, 282: 2871-2879 (2007).
[cited by applicant]
Csak et al., “Fatty Acid and Endotoxin Activate Inflammasomes in Mouse Hepatocytes that Release Danger Signals to Stimulate Immune Cells,” Hepatology, 54: 133-144 (2011).
[cited by applicant]
Csolle et al., “The absence of P2X7 receptors (P2rx7) on non-haematopoietic cells leads to selective alteration in mood-related behaviour with dysregulated gene expression and stress reactivity in mice,” International J…
[cited by applicant]
Cuisset et al., “Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France,” Ann Rheum Dis, 70: 495-499 (2011).
[cited by applicant]
David et al., “IL-18 Underexpression Reduces IL-2 Levels During HIV Infection: A Critical Step Towards the Faulty Cell-Mediated Immunity?” Aids, 14: 2212-2214 (2000).
[cited by applicant]
Davis et al., “The Inflammasome NLRs in Immunity, Inflammation, and Associated Diseases,” Annu Rev Immunol, 29: 707-735 (2011).
[cited by applicant]
Dehner et al., “Parkinsonism in HIV infected patients during antiretroviral therapy—data from a Brazilian tertiary hospital,” Braz J Infect Dis, 20(5): 499-501 (2016).
[cited by applicant]
Dell'antonio et al., “Relief of Inflammatory pain in rats by local use of the selective P2X7 ATP receptor inhibitor, oxidized ATP,” Arthritis & Rheumatism, 46(12):3378-3385 (2002).
[cited by applicant]
Deplano et al., “P2X7 receptor-mediated Nlrp3-infammasome activation is a genetic determinant of macrophage-dependent crescentic glomerulonephritis,” Journal of Leukocyte Biology, 93:127-134 (2013).
[cited by applicant]
Dewannieux et al., “LINE-mediated Retrotransposition of Marked Alu Sequences,” Nature Genetics, 35: 41-48 (2003).
[cited by applicant]
Dhimolea, “Interleukin-1B inhibitors for the treatment of cyropyrin-associated periodic syndrome,” The Application of Clinical Genetics. 4:21-27 (2011).
[cited by applicant]
Diaz-Hernandez et al., “Altered P2X7-receptor level and function in mouse models of Huntington's disease and therapeutic efficacy of antagonist administration,” The FASEB Journal, 23(6):1893-1906 (2009).
[cited by applicant]
Diaz-Hernandez et al., “In vivo P2X7 inhibition reduces amyloid plaques in Alzheimer's disease through GSK3 and secretases,” Neurobiology of Aging, 33:1816-1828 (2012).
[cited by applicant]
Dixit, “Nlrp3 Inflammasome Activation in Type 2 Diabetes: Is It Clinically Relevant?,” Diabetes, 62: 22-24 (2013).
[cited by applicant]
Dostert et al., “Innate Immune Activation through Nalp3 inflammasome sensing of asbestos and silica,” Science, 320(5876):674-677 (2008).
[cited by applicant]
Dridi et al., “ERK1/2 Activation is a Therapeutic Target in Age-related Macular Degeneration,” Proc Natl Acad Sci USA, 109: 13781-13786 (2012).
[cited by applicant]
Duewell et al., “NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals,” Nature, 464:1357-1362 (2010).
[cited by applicant]
Edwards et al., “Nonpeptidic inhibitors of human neutrophil elastase. 7. Design, synthesis, and in vitro activity of a series of pyridopyrimidine trifluoromethyl ketones,” Journal of medicinal chemistry, 39(5):1112-1124…
[cited by applicant]
Eltom et al., “P2X7 receptor and caspase 1 activation are central to airway inflammation observed after exposure to tobacco smoke,” PLOS One, 6(9):1-11 (2011).
[cited by applicant]
Esposito et al., “Role of FAP48 in HIV-associated lipodystrophy,” Journal of Cellular Biochemistry, 113(11): 3446-3454 (2012).
[cited by applicant]
Extended European Search Report for EP Application No. 16756477 mailed Jun. 26, 2018.
[cited by applicant]
Fann et al., “Intravenous immunoglobulin suppresses NLRP1 and NLRP3 inflammasome-mediated neuronal death in ischemic stroke,” Cell Death and Disease, 4:e790 (2013).
[cited by applicant]
Ferrara et al., “Graft-versus-host Disease,” Lancet, 373: 1550-1561 (2009).
[cited by applicant]
Fourie et al., “Percutaneous delivery of carbamazepine and selected N-alkyl and N-hydroxyalkyl analogues,” International Journal of Pharmaceutics, 279(1-2):59-66 (2004).
[cited by applicant]
Fowler et al., “Nucleoside Reverse Transcriptase Inhibitors are Anti-Inflammatory and Target Dry Age-Related Macular Degeneration,” University of Kentucky Uknowledge; Theses and Disserations—Physiology; pp. 1-115 (2014).
[cited by applicant]
Fowler et al., “Nucleoside Reverse Transcriptase Inhibitors Possess Intrinsic Anti-Inflammatory Activity,” Science, 346: 6212, 1000-1003 (2014).
[cited by applicant]
Franchi et al., “The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis,” Nature Immunology, 10: 241-247 (2009).
[cited by applicant]
Franklin et al., “ASC has extracellular and prionoid activities that propagate inflammation,” Nat Immunol, 15(8): 727-737 (2014).
[cited by applicant]
Freeman et al., “Alpha-Synuclein Induces Lysosomal Rupture and Cathepsin Dependent Reactive Oxygen Species Following Endocytosis,” PLOS One, 8(4): e62143 (2013).
[cited by applicant]
Fulgenzi et al., “Periodate oxidized ATP (oATP) reduced hyperalgesia in mice: Involvement of P2X7 receptors and implications for therapy,” International Journal of Immunopathology and Pharmacology, 21(1):61-71 (2007).
[cited by applicant]
Furlan-Freguia et al., “P2X7 receptor signaling contributes to tissue factor-dependent thrombosis in mice,” The Journal of Clinical Investigation, 121(7):2932-2944 (2011).
[cited by applicant]
Furst, “Review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis,” Clinical Therapeutics, 26(12):1960-1975 (2004).
[cited by applicant]
Garcia-Marcos et al., “Role of Sodium in Mitochondrial Membrane Depolarization Induced by P2X7 Receptor Activation in Submandibular Glands,” FEBS Lett, 579: 5407-5413 (2005).
[cited by applicant]
Gartland et al., “Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro,” Calcified Tissue International, 73:361-369 (2003).
[cited by applicant]
Gasse et al., “IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice,” The Journal of Clinical Investigation, 117(12):3786-3799 (2007).
[cited by applicant]
Gasse et al., “Uric Acid Is a Danger Signal Activating NALP3 Inflammasome in Lung Injury Inflammation and Fibrosis,” American Journal of Respiratory and Critical Care Medicine, 179: 903-913 (2009).
[cited by applicant]
Ghasemi et al., “Multiple Sclerosis: Pathogenesis, Symtpoms, Diagnoses and Cell Based Therapy”, Cell J. 19 (1): 1-10 (2017).
[cited by applicant]
Glinskii et al., “Identification of intergenic trans-regulatory RNAs containing a disease-linked SNP sequence and targeting cell cycle progression/differentiation pathways in multiple common human disorders,” Cell Cycle…
[cited by applicant]
Goldback-Mansky et al., “Current status of understanding the pathogenesis and management of patients with NOMID/CINCA,” Curr Rheurmatol Rep, 13(2):123-131 (2011).
[cited by applicant]
Goosen et al., “Physicochemical characterization and solubility analysis of thalidomide and its N-alkyl analogs,” Pharmaceutical Research, 19(1):13-19 (2002).
[cited by applicant]
Goosens et al., “Expression of NLRP3 inflammasome and T cell population markers in adipose tissue are associated with insulin resistance and impaired glucose metabolism in humans,” Molecular Immunology, 50:142-149 (2012…
[cited by applicant]
Gordon et al., “Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice,” Sci. Transl. Med., 10(4066): 1-12 (2018).
[cited by applicant]
Goulaouic et al., “N-versus O-Alkylation of 2,3′-anhydrothymidine: reaction of the obtained pyrimidinium salts with azide ion,” The Journal of Organic Chemistry, 58(11): 3030-3037 (1993).
[cited by applicant]
Griffith et al., “Pure hemozoin is inflammatory in vivo and activates the NALP3 inflammasome via release of uric acid,” The Journal of Immunology, 183:5208-5220 (2009).
[cited by applicant]
Gris et al., “NLRP3 plays a critical role in the development of experimental autoimmune encephalomyelitis by mediating Th1 and Th17 responses,” J Immunol, 185: 974-981 (2010).
[cited by applicant]
Gross et al., “Syk kinase signalling couples to the Nlrp3 inflammasome for anti-fungal host defense,” Nature, 459(21):433-436 (2009).
[cited by applicant]
Guerra et al., “Purinergic receptor regulation of LPS-induced signaling and pathophysiology,” Journal of Endotoxin Research, 9(4):256-263 (2003).
[cited by applicant]
Gulbransen et al., “Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis,” Nat Med, 18(4):600-604 (2012).
[cited by applicant]
Gunther et al., “Neuroprotective effects of the P2 receptor antagonist PPADS on focal cerebral ischaemia-induced injury in rats,” European Journal of Neuroscience, 23:2824-2828 (2006).
[cited by applicant]
Hacker et al., “Deep brain stimulation in early-stage Parkinson disease,” Neurology, 95(4): e393-e401 (2020).
[cited by applicant]
Hattori et al., “Feasibility study of B16 melanoma therapy using oxidized ATP to target purinergic receptor P2X7,” European Journal of Pharmacology, 695:20-26 (2012).
[cited by applicant]
Hazleton et al., “Purinergic Receptors are Required for HIV-1 Infection of Primary Human Macrophages,” J Immunol, 188: 4488-4495 (2012).
[cited by applicant]
He et al., “MEFV E148Q polymorphism is associated with Henoch-Schönlein purpura in Chinese children,” Pediatr Nephrol, 25:2077-2082 (2010).
[cited by applicant]
He et al., “Spinal P2X7 receptor mediates microglia activation-induced neuropathic pain in the sciatic nerve injury rat model,” Behavioural Brain Research, 226:163-170 (2012).
[cited by applicant]
Henao-Mejia et al., “Inflammasome-mediate dysbiosis regulates progression of NAFLD and obesity,” Nature 482(7384):179-185 (2012).
[cited by applicant]
Heneka et al., “NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice,” Nature, 493: 674-682 (2013).
[cited by applicant]
Hentze et al., “Critical Role for Cathepsin B in Mediating Caspase-1-Dependent Interleukin-18 Maturation and Caspase-1-Independent Necrosis Triggered by the Microbial Toxin Nigericin,” Cell Death Differ, 10: 956-968 (20…
[cited by applicant]
Hickey et al., “Available and emerging treatments for Parkinson's disease: a review,” Drug Design, Development and Therapy, 5:241-254 (2011).
[cited by applicant]
Hirsch et al., “Neuroinflammation in Parkinson's disease: a target for neuroprotection?,” Lancet Neurol, 8: 382-397 (2009).
[cited by applicant]
Hoffman et al., “Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome,” Nat Genet, 29(3): 301-305 (2001).
[cited by applicant]
Honore et al., “A-740003 [N-(1-([(Cyanoimino)(5-quinolinylamino) methyl]amino-2,2-dimethylpropyl)-2-(3,4-dimethoxyphenyl) acetamide], a novel and selective P2X7 receptor antagonist, dose-dependently reduces neuropathic …
[cited by applicant]
Hornung et al., “Silica crystals and aluminum salts mediate NALP-3 inflammasome activation via phagosomal destabilization,” Nat Immunol, 9(8): 847-856 (2008).
[cited by applicant]
Huang et al., “The Immune Factors Involved in the Pathogenesis, Diagnosis, and Treatment of Sjogren's Syndrome,” Clinical and Developmental Immunology, 2013(Article ID 160491): 1-6 (2013).
[cited by applicant]
Hugenschmidt et al., “The Cross-sectional and Longitudinal Associations of Diabetic Retinopathy With Cognitive Function and Brain MRI Findings: The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial,” Diab…
[cited by applicant]
Humphreys et al., “Stress-activated Protein Kinase/JNK Activation and Apoptotic Induction by the Macrophage P2X7 Nucleotide Receptor,” J Biol chem, 275: 26792-26798 (2000).
[cited by applicant]
Hurelbrink et al., “Death of Dopaminergic Neurons in Vitro and in Nigral Grafts: Reevaluating the Role of Caspase Activation,” Experimental Neurology, 171: 46-58 (2001).
[cited by applicant]
Iannello et al., “HIV-1 Causes an Imbalance in the Production of Interleukin-18 and Its Natural Atagonist in HIV-Infected Individuals: Implications for Enhanced Viral Replication,” J Infect Dis, 201: 608-617 (2010).
[cited by applicant]
Imagawa et al., “Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results),” Clinic…
[cited by applicant]
Inoue et al., “NLRP3 inflammasome induces chemotactic immune cell migration to the CNS in experimental autoimmune encephalomyelitis,” PNAS, 109(26): 10480-10485 (2012).
[cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US16/19852 dated May 3, 2016.
[cited by applicant]
Ising et al., “NLRP3 inflammasome activation drives tau pathology,” Nature, 575: 669-673 (2019).
[cited by applicant]
Iyer et al., “Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome,” PNAS, 106(48): 20388-20393 (2009).
[cited by applicant]
Jankovic et al., “The Nlrp3 Inflammasome Regulates Acute Graft-versus-host Disease,” J Exp Med, 210: 1899-1910 (2013).
[cited by applicant]
Jelassi et al., “Anthraquinone emodin inhibits human cancer cell invasiveness by antagonizing P2X7 receptors,” Carcinogenesis, 34(7): 1487-1496 (2013).
[cited by applicant]
Jelassi et al., “P2X7 receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness,” Oncogene, 30: 2108-2122 (2011).
[cited by applicant]
Jeong et al., “Structure-Activity Relationships of .beta.-D-(2S,5R)- and .alpha.-D-(2s,5S)-1, 3-Oxathiolanyl Nucleosides as Potential Anti-HIV Agents,” Journal of Medicinal Chemistry, 36(18):2627-2638 (1993).
[cited by applicant]
Ji et al., “P2X7 deficiency Attenuates Hypertension and Renal Injury in Deoxycorticosterone Acetate-Salt Hypertension,” Am J Physiol Renal Physiol, 303: F1207-F1215 (2012).
[cited by applicant]
Ji et al., “P2X7 receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats,” Hypertension Research, 35:173-179 (2012).
[cited by applicant]
Jun et al., “; Extracellular ATP Mediates Necrotic Cell Swelling in SN4741 Dopaminergic Neurons through P2X7 Receptors,” J Biol Chem, 282 (52): 37350-37358 (2007).
[cited by applicant]
Kahlenberg et al., “Inflammasome Activation of IL-18 Results in Endothelial Progenitor Cell Dysfunction in Systemic Lupus Erythematosus,” The Journal of Immunology, 187: 6143-6156 (2011).
[cited by applicant]
Kahlenberg et al., “Mechanisms of Caspase-1 Activation by P2X7 Receptor-Mediated K+ Release,” Am J Physiol Cell Physiol, 286: C1100-1108 (2004).
[cited by applicant]
Kahlenberg et al., “Neutrophil Extracellular Trap-Associated Protein Activation of the NLRP3 Inflammasome Is Enhanced in Lupus Macrophages,” J Immunol, 190: 1217-1226 (2013).
[cited by applicant]
Kakkar et al., “Management of Parkinson's disease: Current and future pharmacotherapy,” European Journal of Pharmacology, 750: 74-81 (2015).
[cited by applicant]
Kakurai et al., “Involvement of P2X7 receptors in retinal ganglion cell death after optic nerve crush injury in rats,” Neuroscience Letters, 534: 237-241 (2013).
[cited by applicant]
Kalbitz et al., “Role of extracellular histones in the cardiomyopathy of sepsis,” The FASEB Journal, 29: 2185-2193 (2015).
[cited by applicant]
Kaneko et al., “DICER1 Deficit Induces Alu RNA Toxicity in Age-related Macular Degeneration,” Nature, 471: 325-330 (2011).
[cited by applicant]
Kawamura et al., “P2X7 Receptors Regulate NKT Cells in Autoimmune Hepatitis 1,” Journal of Immunology, 176: 2152-2160 (2006).
[cited by applicant]
Keating et al., “P2X7 Receptor-Dependent Intestinal Afferent Hypersensitivity in a Mouse Model of Postinfectious Irritable Bowel Syndrome,” The Journal of Immunology, 187: 1467-1474 (2011).
[cited by applicant]
Keller et al., “Thalidomide Inhibits Activation of Caspase-11,” Journal of Immunology, 183: 5593-5599 (2009).
[cited by applicant]
Kerns et al., “Drug-like properties: concepts, structure design and methods from ADME to toxicity optimization,” Elsevier (2008).
[cited by applicant]
Kerur et al., “TLR-Independent and P2X7-Dependent Signaling Mediate Alu RNA-Induced NLRP3 Inflammasome Activation in Geographic Atrophy,” Invest Ophthalmol Vis Sci, 54: 7395-7401 (2013).
[cited by applicant]
Killeen et al., “Signaling Through Purinergic Receptors for ATP Induces Human Cutaneous Innate and Adaptive Th17 Responses: Implications in the Pathogenesis of Psoriasis,” The Journal of Immunology, 190: 4324-4336 (2013…
[cited by applicant]
Killinger et al., “The vermiform appendix impacts the risk of developing Parkinson's disease,” Sci Transl Med., 10(465): 1-32 (2018).
[cited by applicant]
Kim et al., “NLRP3 Inflammasome Knockout Mice Are Protected Against Ischemic but Not Cisplatin-Induced Acute Kidney Injury,” J Pharmacol Exp Ther, 346: 465-472 (2013).
[cited by applicant]
Kimbler et al., “Activation of P2X7 Promotes Cerebral Edema and Neurological Injury After Traumatic Brain Injury in Mice,” PLoS One, 7(7): 1-10 (2012).
[cited by applicant]
Kobayashi et al., “Induction of the P2X7 Receptor in Spinal Microglia in a Neuropathic Pain Model,” Neuroscience Letters, 504: 57-61 (2011).
[cited by applicant]
Koo et al., “ESX-1-dependent cytolysis in lysosome secretion and inflammasome activation during mycobacterial infection,” Cellular Microbiology, 10(9): 1866-1878 (2008).
[cited by applicant]
Koo et al., “Evidence for IL-1 Receptor Blockade as a Therapeutic Strategy for the Treatment of Depression,” Curr Opin Investing Drugs, 10(7): 664-671 (2009).
[cited by applicant]
Koprich et al., “Neuroinflammation mediated by IL-1? increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease,” Journal of Neuroinflammation, 5:8 (2008).
[cited by applicant]
Kubes et al., “Reviews in Basic And Clinical Gastroenterology And Hepatology,” Gastroenterology, 143: 1158-1172 (2012).
[cited by applicant]
Kubes et al., “Sterile Inflammation in the Liver,” Gastroenterology, 143: 1158-1172 (2012).
[cited by applicant]
Kubota et al., “Cryopyrin-Associated Periodic Syndromes: Background and Therapeutics,” Mod Rheumatol, 20: 213-221 (2010).
[cited by applicant]
Kuemmerle-Deschner et al., “Canakinumab (ACZ885, a fully human IgG1 anti-IL-1b mAb) Induces Sustained remission in Pediatric Patients with Cryopyrin-Associated Periodic Syndrome (CAPS),” Arthritis Research and Therapy, …
[cited by applicant]
Labasi et al., “Absence of the P2X7 Receptor Alters Leukocyte Function and Attenuates an Inflammatory Response,” The Journal of Immunology, 168: 6436-6445 (2002).
[cited by applicant]
Lee et al., “Upregulated NLRP3 Inflammasome Activation in Patients with Type 2 Diabetes,” Diabetes, 62: 194-204 (2013).
[cited by applicant]
Lewis et al., “Mitochondrial Toxicity of NRTI Antiviral Drugs: An Integrated Cellular Perspective,” Nat Rev Drug Discov, 2: 812-822 (2003).
[cited by applicant]
Li et al., “Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation,” Nature Medicine, 14(5): 501-503 (2008).
[cited by applicant]
Li et al., “Mechanisms of ATP Release by Human Trabecular Meshwork Cells the Enabling Step in Purinergic Regulations of Aqueous Humor Outflow,” J Cell Physiol, 227(1): 172-182 (2012).
[cited by applicant]
Li et al., “MicroRNA-30e regulates neuroinflammation in MPTP model of Parkinson's disease by targeting Nlrp3,” Human Cell, 31: 106-115 (2018).
[cited by applicant]
Li et al., “Propionibacterium acnes Activates the NLRP3 Inflammasome in Human Sebocytes,” Journal of Investigative Dermatology, 134: 2747-2756 (2014).
[cited by applicant]
Liu et al., “Expression of the NLRP3 Inflammasome in Cerebral Cortex After Traumatic Brain Injury in a Rat Model,” Neurochem Res, 38: 2072-2083 (2013).
[cited by applicant]
Liu et al., “The role of inflammasome in Alzheimer's disease,” Ageing Research Reviews, 15: 6-15 (2014).
[cited by applicant]
Lommatzsch et al., “Extracellular Adenosine Triphosphate and Chronic Obstructive Pulmonary Disease,” Am J Respir Crit Care Med, 181, 928-934 (2010).
[cited by applicant]
Lopez-Castejon et al., “P2X7 Receptor-Mediated Release of Cathepsins from Macrophages is a Cytokine-Independent Mechanism Potentially Involved in Joint Diseases,” Journal of Immunology, 185: 2611-2619 (2010).
[cited by applicant]
Lu et al., “Uncoupling protein 2 deficiency aggravates astrocytic endoplasmic reticulum stress and nod-like receptor protein 3 inflammasome activation,” Neurobiology of Aging, 35: 421-430 (2014).
[cited by applicant]
Lucattelli et al., “P2X7 Receptor Signaling in the Pathogenesis of Smoke-Induced Lung Inflammation and Emphysema,” Am J Respir Cell Mol Biol, 44: 423-239 (2011).
[cited by applicant]
Macri et al., “Serum levels of interleukin 1β, interleukin 8 and tumour necrosis factor α as markers of gastric cancer,” Biomarkers, 11(2): 184-193 (2006).
[cited by applicant]
Manda et al., “Highly active antiretroviral therapy drug combination induces oxidative stress and mitochondrial dysfunction in immortalized human blood-brain barrier endothelial cells,” Free Radical Biology & Medicine, …
[cited by applicant]
Mangialasche et al., “Alzheimer's disease: clinical trials and drug development” LancetNeurol, 9(7):702-716 (2010).
[cited by applicant]
Mansson et al., “NOD-like receptors in the human upper airways: a potential role in nasal polyposis,” Allergy, 66: 621-628 (2011).
[cited by applicant]
Mao et al., “Nitric Oxide Suppresses NLRP3 Inflammasome Activation and Protects Against LPS-Induced Septic Shock,” Cell Research 23: 201-212 (2013).
[cited by applicant]
Mao et al., “The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson's Disease in Rats,” Neurochem Res, 42:1104-1115 (2017).
[cited by applicant]
Marcellino et al., “On the Role of P2X7 Receptors in Dopamine Nerve Cell Degeneration in a Rat Model of Parkinson's Disease: Studies with the P2X7 Receptor Antagonist A-438079,” J Neural Transm, 117: 681-687 (2010).
[cited by applicant]
Mariathasan et al., “Cryopyrin Activates the Inflammasome in Response to Toxins and ATP,” Nature, 440: 228-232 (2006).
[cited by applicant]
Mariathasan et al., “Differential Activation of the Inflammasome by Caspase-1 Adaptors ASC and Ipaf,” Nature, 430: 213-218 (2004).
[cited by applicant]
Martinon et al., “Gout-associated Uric Acid Crystals Activate the NALP3 Inflammasome,” Nature, 440: 237-241 (2006).
[cited by applicant]
Martinon et al., “The Inflammasome: A Molecular Platform Triggering Activation of Inflammatory Caspases and Processing of ProIL-Beta,” Mol Cell, 10: 417-426 (2002).
[cited by applicant]
Martinon et al., “The Inflammasomes: Guardians of the Body,” Annu Rev Immunol, 27: 229-265 (2009).
[cited by applicant]
Masters et al., “Activation of the NLRP3 Inflammasome by Islet Amyloid Polypeptide Provides a Mechanism for Enhanced IL-1b in type 2 Diabetes,” Nature Immunology, 11(10): 897-905 (2010).
[cited by applicant]
Masuda et al., “Syk Inhibitors as Treatment for Allergic Rhinitis,” Pulmonary Pharmacology and Therapeutics, 21: 461-467 (2008).
[cited by applicant]
Matute et al., “P2X7 Receptor Blockade Prevents ATP Excitotoxicity in Oligodendrocytes and Ameliorates Experimental Autoimmune Encephalomyelitis,” The Journal of Neuroscience, 27(35): 9525-9533 (2007).
[cited by applicant]
McClellan et al., “High-Mobility Group Box 1: A Novel Target for Treatment of Pseudomonas aeruginosa Keratitis,” The Journal of Immunology, 194: 1776-1787 (2015).
[cited by applicant]
McCoy et al., “Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease,” The Journal of Neuroscien…
[cited by applicant]
McDonald et al., “Intravascular Danger Signals Guide Neutrophils to Sites of Sterile Inflammation,” Science, 330: 362-366 (2010).
[cited by applicant]
Minagar et al., “The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis,” Journal of the Neurological Scienc…
[cited by applicant]
Mirsattari et al., “Parkinsonism With HIV Infection,” Movement Disorders, 13(4): 684-689 (1998).
[cited by applicant]
Mishra et al., “Nitric Oxide Controls the Immunopathology of Tuberculosis by Inhibiting NLRP3 Inflammasome-Dependent Processing of IL-1,” Nature Immunology, 14(1): 52-61 (2013).
[cited by applicant]
Mittag et al., “Retinal Damage after 3 to 4 Months of Elevated Intraocular Pressure in a Rat Glaucoma Model,” Invest Ophthalmol Vis Sci., 41: 3451-3459 (2000).
[cited by applicant]
Mittal et al., “β2-Adrenoreceptor is a Regulator of the α-Synuclein Gene Driving Risk of Parkinson's Disease,” Science, 357(6354): 891-898 (2017).
[cited by applicant]
Mizutani et al., “Nucleoside Reverse Transcriptase Inhibitors Suppress Laser-Induced Choroidal Neovascularization in Mice,” Invest Ophthalmol Vis Sci, 12: 7122-7129 (2015).
[cited by applicant]
Mochizuki et al., “An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease,” PNAS, 98(19): 10918-10923 (2001).
[cited by applicant]
Morgan et al., “Phase I study of cisdiamminedichloroplatinum in combination with azidothymidine in the treatment of patients with advanced malignancies” Cancer Chemotherapy Pharmacol, 51: 459-464 (2003).
[cited by applicant]
Nakahira et al., “Autophagy Proteins Regulate Innate Immune Responses by Inhibiting the Release of Mitochondrial DNA Mediated by the NALP3 Inflammasome,” Nat Immunol, 12: 222-230 (2011).
[cited by applicant]
Nakao et al., “Infiltration of COX-2-expressing macrophages is a prerequisite for IL-1?-induced neovascularization and tumor growth,” J Clin Invest, 115(11): 2979-2991 (2005).
[cited by applicant]
Noh et al., “Cordycepin inhibits IL-1α-induced MMP-1 and MMP-3 expression in rheumatoid arthritis synovial fibroblasts,” Rheumatology, 48: 45-48 (2009).
[cited by applicant]
Nykanen et al., “ATP Requirements and Small Interfering RNA Structure in the RNA Interference Pathway,” Cell, 107: 309-321 (2001).
[cited by applicant]
O'Brien et al., “A bioluminescent caspase-1 activity assay rapidly monitors inflammasome activation in cells,” Journal of Immunological Methods, 447: 1-13 (2017).
[cited by applicant]
Okamoto et al., “Constitutively Active Inflammasome in Human Melanoma Cells Mediating Autoinflammation via Caspase-1 Processing and Secretion of Interleukin-1β,” The Journal of Biological Chemistry, 285(9): 6477-6488 (2…
[cited by applicant]
Ostertag et al., “Induction of Endogenous Virus and of Thymidine Kinase by Bromodeoxyuridine in Cell Cultures Transformed by Friend Virus,” Proc Natl Acad Sci USA, 71: 4980-4985 (1974).
[cited by applicant]
Ou et al., “NLRP3 Inflammasome Inhibition Prevents α-Synuclein Pathology by Relieving Autophagy Dysfunction in Chronic MPTP-Treated NLRP3 Knockout Mice,” Molecular Neurobiology, 58: 1303-1311 (2020).
[cited by applicant]
Ozaki et al., “Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives,” Journal of Inflammation Research, 8: 15-27 (2015).
[cited by applicant]
Pamuk et al., “Spleen Tyrosine Kinase Inhibition in the Treatment of Autoimmune, Allergic and Autoinflammatory Diseases,” Arthritis Research and Therapy, 12:222, 1-11 (2010).
[cited by applicant]
Pelegrin et al., “Pannexin-1 Mediates Large Pore Formation and Interleukin-1beta Release by the ATP-gated P2X7 Receptor,” EMBO J, 25: 5071-5082 (2006).
[cited by applicant]
Peng et al., “Systemic Administration of an Antagonist of the ATP-Sensitive Receptor P2X7 Improves Recovery After Spinal Cord Injury,” PNAS, 106(30): 12489-12493 (2009).
[cited by applicant]
Pereira et al., “Activation of NLRC4 by Flagellated Bacteria Triggers Caspase-1-Dependent and -Independent Responses to Restrict Legionella Pneumophila Replication in Macrophages and in Vivo,” The Journal of Immunology,…
[cited by applicant]
Petrilli et al., “Activation of the NALP3 Inflammasome is Triggered by Low Intracellular Potassium Concentration,” Cell Death Differ, 14: 1583-1589 (2007).
[cited by applicant]
Pubchem.Schembl 15257684. Feb. 13, 2015; pp. 1-10.
[cited by applicant]
Puchem. CID 59120361. Aug. 20, 2012; pp. 1-10.
[cited by applicant]
Qin et al., “Propionibacterium Acnes Induces 1L-1b Secretion via the NLRP3 Inflammasome in Human Monocytes,” Journal of Investigative Dermatology, 134: 381-388 (2014).
[cited by applicant]
Qu et al., “Pannexin-1 is Required for ATP Release During Apoptosis but not for Inflammasome Activation,” J Immunol, 186: 6553-6561 (2011).
[cited by applicant]
Raffaghello et al., “The P2X7 Receptor Sustains the Growth of Human Neuroblastoma Cells Through a Substance P-Dependent Mechanism,” Cancer Res, 66(2): 907-914 (2006).
[cited by applicant]
Rathinam et al., “TRIF Licenses Caspase-11-Dependent NLRP3 Inflammasome Activation by Gram-Negative Bacteria,” Cell, 150: 606-619 (2012).
[cited by applicant]
Rautio et al., “Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation,” European journal of pharmaceutical sciences, 11(2):157-163 (2000).
[cited by applicant]
Rawat et al., “Inflammasome Up-Regulation and Activation in Dysferlin-Deficient Skeletal Muscle,” The American Journal of Pathology, 176(6): 2891-2900 (2010).
[cited by applicant]
Ribeiro et al., “Activation of innate immune defense mechanisms contributes to polyomavirus BK-associated nephropathy,” Kidney International, 81: 100-111 (2012).
[cited by applicant]
Rimessi et al., “Mitochondrial Ca2+ dependent NLRP3 activation exacerbates the Pseudomonas aeruginosa-driven inflammatory response in cystic fibrosis,” Nature Communications, 6(Article No. 6201): 1-16 (2015).
[cited by applicant]
Riteau et al., “ATP Release and Purinergic Signaling: A Common Pathway for Particle-Mediated Inflammasome Activation,” Cell Death Dis, 3: e403 (2012).
[cited by applicant]
Ritter et al., “Schistosoma Mansoni Triggers Dectin-2, which Activates the Nlrp3 Inflammasome the Alters Adaptive Immune Responses,” PNAS, 107(47): 20459-20464 (2010).
[cited by applicant]
Rosales-Reyes et al., “Burkholderia Cenocepacia Type VI Secretion System Mediates Escape of Type II Secreted Proteins into the Cytoplasm of Infected Macrophages,” PloS One, 7(7): e41726, 1-14 (2012).
[cited by applicant]
Ryu et al., “Block of Purinergic P2X7 Receptor is Neuroprotective in an Animal Model of Alzheimer's Disease,” Neuropharmacology and Neurotoxicology, 19(17): 1715-1719 (2008).
[cited by applicant]
Saladino et al., “Ozonation of thionucleosides. A new chemical transformation of 4-thiouracil and 6-thioguanine nucleosides to cytosine and adenosine counterparts,” Tetrahedron, 51(12): 3607-3616 (1995).
[cited by applicant]
Samad et al., “Interleukin-1β-mediated induction of Cox-2 in the CNS contributes to inflammatory pain hypersensitivity,” Nature, 410: 471-475 (2001).
[cited by applicant]
Sandanger et al., “The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury,” Cardiovascular Research, 99: 164-174 (2013).
[cited by applicant]
Sasaki et al., “Immunohistochemical Study of Fas, Fas Ligand and Interleukin-1b Converting Enzyme Expression in Human Prostatic Cancer,” British Journal of Urology, 81: 852-855 (1998).
[cited by applicant]
Schroder et al., “The Inflammasomes,” Cell, 140: 821-832 (2010).
[cited by applicant]
Serrano et al., “Evidence of association of the NLRP1 gene with giant cell arteritis,” Ann Rheum Dis, 72(4): 628-630 (2013).
[cited by applicant]
Sharp et al., “P2X7 Deficiency Suppresses Development of Experimental Autoimmune Encephalomyelitis,” Journal of Neuroinflammation, 5(33): 1-13 (2008).
[cited by applicant]
Shin et al., “Self Double-Stranded (ds) DNA induced 1L-1b Production From Human Monocytes by Activating NLRP3 Inflammasome in the Presence of Anti-dsDNA Antibodies,” J Immunol, 190: 1407-1415 (2013).
[cited by applicant]
Shio et al., “Malarial Hemozoin Activates the NLRP3 Inflammasome Through Lyn and Syk Kinases,” PLOS Pathogens, 5(8): E1000559, 1-14 (2009).
[cited by applicant]
Singhal et al., “Inflammasomes in neuroinflammation and changes in brain function: a focused review,” Frontier Neurosci, 8(Article 315): 1-13 (2014).
[cited by applicant]
Sivaraj et al., “Ocular manifestations of systemic lupus erythematosus,” Rheumatology, 46: 1757-1762 (2007).
[cited by applicant]
Soderlund et al., “Elevation of cerebrospinal fluid interleukin-1β in bipolar disorder,” J Psychiatry Neurosci, 36(2): 114-118 (2011).
[cited by applicant]
Sokal et al., “A dose ranging study of the pharmacokinetics, safety, and preliminary efficacy of lamivudine in children and adolescents with chronic hepatitis B,” Antimicrobial agents and chemotherapy, 44(3):590-597 (20…
[cited by applicant]
Solini et al., “Increased P2X7 Receptor Expression and Function in Thyroid Papillary Cancer: A New Potential Marker of the Disease?,” Endocrinology, 149(1): 389-396 (2007).
[cited by applicant]
Song et al., “NLRP3 Phosphorylation Is an Essential Priming Event for Inflammasome Activation,” Molecular Cell, 68: 185-197 (2017).
[cited by applicant]
Sorge et al., “Genetically Determined P2X7 Receptor Pore Formation Regulates Variability in Chronic Pain Sensitivity,” Nat Med, 18: 595-599 (2012).
[cited by applicant]
Stienstra et al., “Inflammasome is a Central Player in the Induction of Obesity and Insulin Resistance,” PNAS, 108(37): 15324-15329 (2011).
[cited by applicant]
Stylianou et al., “Raised Serum Levels of Interleukin-18 is Associated with Disease Progression and May Contribute to Virological Treatment Failure in HIV-1-Infected Patients,” Clin Exp Immunol, 132: 462-466 (2003).
[cited by applicant]
Surprenant et al., “The Cytolytic P2Z Receptor for Extracellular ATP Identified as a P2X Receptor (P2X7),” Science, 272: 735-738 (1996).
[cited by applicant]
Sutterwala et al., “NALP3: a Key Player in Caspase-1 Activation,” Journal of Endotoxin Research, 12(4): 1-6 (2006).
[cited by applicant]
Syberg et al., “Genetic Background Strongly Influences the Bone Phenotype of P2X7 Receptor Knockout Mice,” Journal of Osteoporosis, Article ID 391097 (2012).
[cited by applicant]
Tansey et al., “Neuroinflammation in Parkinson's disease: Its role in neuronal death and implications for therapeutic intervention,” Neurobiology of Disease, 37(3): 510-518 (2010).
[cited by applicant]
Tarallo et al., “DICEr1 Loss and Alu RNA Induce Age-Related Macular Degeneration via the NLRP3 Inflammasome and MyD88,” Cell, 149: 847-859 (2012).
[cited by applicant]
Taylor et el., “P2X7 Deficiency Attenuates Renal Injury in Experimental Glomerulonephritis,” J Am Soc Nephrol, 20: 1275-1281 (2009).
[cited by applicant]
Thakur et al., “Caspase-1 Inhibitor Reduces Severity of Pseudomonas Aeruginosa Keratitis in Mice,” Invest Ophthalmol Vis Sci, 45: 3177-3184 (2004).
[cited by applicant]
Thakur et al., “Regulation of Pseudomonas Aeruginosa Corneal Infection in IL-1b Converting Enzyme (ICE, caspase-1) Deficient Mice,” Current Eye Research, 29(4-5): 225-233 (2004).
[cited by applicant]
Tisch et al., Parkinsonism in HIV-Infected Patients on Highly Active Antiretroviral Therapy, Neurology, 73(5): 401-403 (2009).
[cited by applicant]
Toma et al., “Pathogenic Vibrio Activate NLRP3 Inflammasome via Cytotoxins and TLR/Nucleotide-Binding Oligomerization Domain-Mediated NF-kB Signaling,” The Journal of Immunology, 184: 5287-5297 (2010).
[cited by applicant]
Tomura et al., “Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury,” Journal of Cerebral Blood Flow & Metabolism, 32: 1939-1947 (2012).
[cited by applicant]
Tsai et al., “Epigallocatechin-3 Gallate Prevents Lupus Nephritis Development in Mice via Enhancing the Nrf2 Antioxidant Pathway and Inhibiting NLRP3 Inflammasome Activation,” Free Radical Biology and Medicine, 51: 744-…
[cited by applicant]
Ture-Ozdemir et al., “Pro-inflammatory cytokine and caspase-1 responses to pattern recognition receptor activation of neutrophils and dendritic cells in Behcet's disease,” Rheumatology, 52:800-805 (2013).
[cited by applicant]
Usui et al., “Critical Role of Caspase-1 in Vascular Inflammation and Development of Atherosclerosis in Western Diet-fed Apolipoprotein E-deficient Mice,” Biochemical and Biophysical Research Communications, 425: 162-16…
[cited by applicant]
Van Praag et al., “Stable Concentrations of Zidovudine, Stavudine, Lamivudine, Abacavir, and Nevirapine in Serum and Cerebrospinal Fluid during 2 Years of Therapy,” Antimicrobial Agents and Chemotherapy, 46(3): 896-899 …
[cited by applicant]
Vanaja et al., “Bacterial RNA:DNA hybrids are activators of the NLRP3 inflammasome,” PNAS, 111(21): 7765-7770 (2014).
[cited by applicant]
Vandanmagsar et al., “The NALP3/NLRP3 Inflammasome Instigates Obesity-Induced Autoinflammation and Insulin Resistance,” Nat Med, 17(2): 179-188 (2011).
[cited by applicant]
Vergani et al., “Effects of the Purinergic Inhibitor Oxidized ATP in a model of Islet Allograft Rejection,” Diabetes, 62: 1665-1675 (2013).
[cited by applicant]
Vergani et al., “Long-Term Heart Transplant Survival by Targeting the Ionotropic Purinergic Receptor P2X7,” Circulation, 127: 463-475 (2013).
[cited by applicant]
Verheyden et al., “Halo sugar nucleosides. IV. Synthesis of some 4′,5′-unsaturated pyrimidine nucleosides,” The Journal of Organic Chemistry, 39(24): 3573-3579 (1974).
[cited by applicant]
Vilaysane et al., “The NLRP3 Inflammasome Promotes Renal Inflammation and Contributes to CKD,” J Am Soc Nephrol, 21: 1732-1744 (2010).
[cited by applicant]
Wahner et al., “Inflammatory Cytokine Gene Polymorphisms and Increased Risk of Parkinson Disease,” Arch Neurol., 64: 836-840 (2007).
[cited by applicant]
Wang et al., “Metabolic inflammation exacerbates dopaminergic neuronal degeneration in response to acute MPTP challenge in type 2 diabetes mice,” Experimental Neurology, 251: 22-29 (2014).
[cited by applicant]
Wang et al., “P2X7 Receptor Inhibition Improves Recovery After Spinal Cord Injury,” Nature Medicine, 10(8): 821-827 (2004).
[cited by applicant]
Wang et al., “Quercetin and Allopurinol Reduce Liver Thioredoxin interacting Protein to Alleviate Inflammation and Lipid Accumulation in Diabetic Rats,” British Journal of Pharmacology, 169: 1352-1371 (2013).
[cited by applicant]
Weaver et al., “The design and synthesis of nucleoside triphosphate isosteres as potential inhibitors of HIV reverse transcriptase,” Tetrahedron, 53(15): 5537-5562 (1997).
[cited by applicant]
Weber et al., “Lack of the Purinergic Receptor P2X7 Results in Resistance to Contact Hypersensitivity,” J Exp Med, 27(12): 2609-2619 (2010).
[cited by applicant]
Wegrzyn et al., “Rheumatoid arthritis after 9 years of human immunodeficiency virus infection: possible contribution of tritherapy,” The Journal of Rheumatology, 29: 2232-2234 (2002).
[cited by applicant]
Wilhelm et al., “Graft-versus-host Disease is Enhanced by Extracellular ATP Activating P2X7R,” Nat Med, 16: 1434-1438 (2010).
[cited by applicant]
Wong et al., “The 3 Year Incidence and Cumulative Prevalence of Retinopathy: The Atherosclerosis Risk In Communities Study,” Am J Ophthalmol, 143(6): 970-976 (2007).
[cited by applicant]
Woods et al., “P2x7 Receptor Activation Induces Inflammatory Responses in Salivary Gland Epithelium,” Am J Physiol Cell Physiol, 303: S790-S801 (2012).
[cited by applicant]
Wree et al., “NLRP3 inflammasome activation is required for fibrosis development in NAFLD,” J Mol Med (Berl)., 92(10): 1069-1082 (2014).
[cited by applicant]
Wu et al., “Functional Decreases in P2X7 Receptors are Associated with Retinoic Acid- Induced Neuronal Differentiation of Neuro-2a Neuroblastoma Cells,” Cellular Signaling, 21: 881-891 (2009).
[cited by applicant]
Xia et al., “Neurons Respond Directly to Mechanical Deformation With Pannexin-Mediated ATP Release and Autostimulation of P2X7 Receptors,” J Physiol, 590(10): 2285-2304 (2012).
[cited by applicant]
Xu et al., “Innate immune sensing of bacterial modifications of; Rho GTPases by the Pyrin inflammasome,” Nature, 513: 237-241 (2014).
[cited by applicant]
Xu et al., “Mycoplasma Hyorhinis Activates the NLRP3 Inflammasome and Promotes Migration and Invasion of Gastric Cancer Cells,” PLOS One, 8(11): 1-14 (2013).
[cited by applicant]
Yajima et al., “Critical Role of Bone Marrow Apoptosis-Associated Speck Like Protein, an Inflammasome Adaptor Molecule, in Neointimal Formation After Vascular Injury in Mice,” Circulation, 117: 3079-3087 (2008).
[cited by applicant]
Yamin et al., “Activation of the Native 45-kDa Precursors Form of Interleukin-1-Converting Enzyme,” J Biol Chem, 271: 13272-13282 (1996).
[cited by applicant]
Yarchoan et al., “Response of Humanimmunodeficiency-Virus-Associated Neurological Disease To 3′-Azido-3′-Deoxythymidine,” Lancet, 132-135 (1987).
[cited by applicant]
Yasukawa et al., “An ITAM-Syk-CARD9 signalling axis triggers contact hypersensitivity by stimulating IL-1 production in dendritic cells,” Nature Communications, 5:3755 (2014).
[cited by applicant]
Youm et al., “Elimination of the NLRP3-ASC Inflammasome Protects Against Chronic Obesity-Induced Pancreatic Damage,” Endocrinology, 152(11): 4039-4045 (2011).
[cited by applicant]
Zaborina et al., “P2Z-Independent and P2Z Receptor-Mediated Macrophage Killing by Pseudomonas Aeruginosa Isolated from Cystic Fibrosis Patients,” Infection and Immunity, 67(10):5231-5242 (1999).
[cited by applicant]
Zaborina et al., “Secreted Products of a Nonmucoid Pseudomonas Aeruginosa Strain Induce Two Modes of Macrophage Killing: External—ATP-dependent, P2Z-Receptor-Mediated Necrosis and ATP-Independent, Caspase-Mediated Apopt…
[cited by applicant]
Zhang et al., “Cardiac Fibroblasts Contribute to Myocardial Dysfunction in Mice with Sepsis: The Role of NLRP3 Inflammasome Activation,” PLoS One, 9(9): e107639 (2014).
[cited by applicant]
Zhang et al., “Effects of Thalidomide on Angiogenesis and Tumor Growth and Metastasis of Human Hepatocellular Carcinoma in Nude Mice,” World J Gastroenterol, 11(2): 216-220 (2005).
[cited by applicant]
Zhang et al., “Enterohemorrhagic
[cited by applicant]
Zhao et al., “Bay11-7082 attenuates murine lupus nephritis via inhibiting NLRP3 inflammasome and NF-kB activation,” International Immunopharmacology, 17: 116-122 (2013).
[cited by applicant]
Zhao et al., “P2X7 Blockade Attenuates Murine Lupus Nephritis by Inhibiting Activation of the NLRP3/ASC/Caspase 1 Pathway,” Arthritis and Rheumatism, 65(12): 3176-3185 (2013).
[cited by applicant]
Zheng et al., “Silence of NLRP3 Suppresses Atherosclerosis and Stabilizes Plaques in Apolipoprotein E-Deficient Mice,” Mediators of Inflammation, 2014(Article ID: 507208): 1-8 (2014).
[cited by applicant]
Zhou et al., “MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson's disease,” Molecular Neurodegeneration, 11(28): 1-15 (2016).
[cited by applicant]
Ziganshin et al., “Effect of PPADS on P2X Receptor-Mediated Responses of Human Blood Vessels,” Bulletin of Experimental Biology and Medicine, 137(3): 284-287 (2004).
[cited by applicant]
Lai, et al., HIV-tuberculosis-associated immune reconstitution inflammatory syndrome is characterized by Toll-like receptor and inflammasome signalling, Nature Communications | 6:8451, Mar. 13, 2015, pp. 1-11.
[cited by applicant]
Marais, et al., Inflammasome Activation Underlying Central Nervous System Deterioration in HIV-Associated Tuberculosis, Inflammasomes in TBM-IRIS ⋅ JID 2017:215 (Mar. 1), pp. 677-686.
[cited by applicant]
Bandera, et al., The nlrP3 inflammasome is Upregulated in HIV-infected antiretroviral Therapy-Treated individuals with Defective immune recovery, Frontiers in Immunology, Feb. 2018 | vol. 9 | Article 214IN, pp. 1-8.
[cited by applicant]
Guerville, et al., Mechanisms of systemic low-grade inflammation in HIV patients on long-term suppressive antiretroviral therapy: the inflammasome hypothesis, AIDS 2023, vol. 37 No 7, pp. 1-12.
[cited by applicant]